MedTrace Logo

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 860

Last updated 2026-05-22

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Conditions

  • Solid Cancer

Interventions

DRUG

R-DXd

R-DXd will be administered as an intravenously (IV) infusion

DRUG

Paclitaxel

Paclitaxel will be administered as an IV infusion

DRUG

Topotecan

Topotecan will be administered as an IV infusion

DRUG

PLD

PLD will be administered as an IV infusion

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-27
Primary Completion
2028-02-29
Completion
2030-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • China
  • Czechia
  • Finland
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Poland
  • Portugal
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161025 on ClinicalTrials.gov